Ecological impact of MCB3837 on the normal human microbiota

International Journal of Antimicrobial Agents

Volumn 44, Issue 2, 2014, Pages 125-130

  Rashid, Mamun Ur ^a   Dalhoff, Axel ^b   Bäckström, Tobias ^a   Björkhem Bergman, Linda ^a   Panagiotidis, Georgios ^a   Weintraub, Andrej ^a   Nord, Carl Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

MCB3681; MCB3837; Normal human microbiota

Indexed keywords

MCB 3681; MCB 3837; OXAZOLIDINONE DERIVATIVE; PRODRUG; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL COUNT; BACTEROIDES; BACTEROIDES FRAGILIS; BIFIDOBACTERIUM; CANDIDA; CANDIDA ALBICANS; CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG SALIVA LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROBACTERIACEAE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FECES MICROFLORA; FUSOBACTERIUM; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INJECTION SITE PHLEBITIS; INTESTINE FLORA; LACTOBACILLUS; LEPTOTRICHIA; MALE; MICROBIAL IDENTIFICATION; MICROCOCCUS; MICROFLORA; MINIMUM INHIBITORY CONCENTRATION; MORNING DOSAGE; MULTIPLE DRUG DOSE; NEISSERIA; NORMAL HUMAN; NOSE MICROFLORA; OPEN STUDY; OROPHARYNGEAL MICROFLORA; PREVOTELLA; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; SIDE EFFECT; SKIN FLORA; STAPHYLOCOCCUS AUREUS; VEILLONELLA; BACTERIA; CLASSIFICATION; DRUG EFFECTS; GASTROINTESTINAL TRACT; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; NOSE CAVITY; OROPHARYNX; SKIN; TIME;

ANTI-BACTERIAL AGENTS; BACTERIA; CANDIDA; GASTROINTESTINAL TRACT; HEALTHY VOLUNTEERS; HUMANS; MALE; MICROBIOLOGICAL TECHNIQUES; MICROBIOTA; NASAL CAVITY; OROPHARYNX; OXAZOLIDINONES; PRODRUGS; QUINOLONES; SKIN; TIME FACTORS;

EID: 84905563516     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.03.016     Document Type: Article

References (30)

1. A. Sullivan, C. Edlund, and C.E. Nord Effect of antimicrobial agents on the ecological balance of human microflora Lancet Infect Dis 1 2001 101 114
2. G.L. Simon, and S.L. Gorbach The human intestinal microflora Dig Dis Sci 31 1986 147S 162S
3. I. Cho, and M.J. Blaser The human microbiome: at the interface of health and disease Nat Rev Genet 13 2012 260 270
4. M.U. Rashid, A. Weintraub, and C.E. Nord Effect of new antimicrobial agents on the ecological balance of human microflora Anaerobe 18 2012 249 253
5. M.J. Pucci, and K. Bush Investigational antimicrobial agents of 2013 Clin Microbiol Rev 26 2013 792 821
6. M. Kresken, and J. Brauers In vitro activity of the novel antibacterial MCB3681 against selected Gram-positive and -negative bacteria compared to established antibiotics 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM Press, San Francisco, CA/Washington, DC, September 27-30 2006 [poster F1-1967]
7. S. Schubert, and A. Dalhoff Low propensity for development of resistance to MCB3681, the active moiety of Oxaquin (MCB3837), in Gram-positive bacteria with vancomycin-, linezolid-, methicillin-, and/or ciprofloxacin-resistance 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM Press, San Francisco, CA/Washington, DC, September 27-30 2006 [poster F1-1908]
8. M.F. Gordeev, C. Hackbarth, M.R. Barbachyn, L.S. Banitt, J.R. Gage, and G.W. Luehr et al. Novel oxazolidinone-quinolone hybrid antimicrobials Bioorg Med Chem Lett 13 2003 4213 4216
9. V. Pokrovskaya, and T. Baasov Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance Expert Opin Drug Discov 5 2010 883 902
10. H. Brötz-Oesterhelt, and N.A. Brunner How many modes of action should an antibiotic have? Curr Opin Pharmacol 8 2008 564 573
11. M. Rashid, A. Weintraub, and C.E. Nord Comparative effects of the immediate and the extended release formulations of ciprofloxacin on normal human intestinal microflora J Chemother 23 2011 145 149
12. C.E. Nord, E. Sillerstrom, and E. Wahlund Effect of tigecycline on normal oropharyngeal and intestinal microflora Antimicrob Agents Chemother 50 2006 3375 3380
13. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.L. Landry, and M.A. Pfaller Manual of clinical microbiology 9th ed. 2007 ASM Press Washington, DC
14. H. Huang, A. Weintraub, H. Fang, and C.E. Nord Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of Clostridium difficile infections J Clin Microbiol 47 2009 3729 3731
15. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 9th ed. 2012 CLSI Wayne, PA Document M07-A9
16. Clinical and Laboratory Standards Institute Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard 8th ed. 2012 CLSI Wayne, PA Document M11-A8
17. S.R. Norrby, C.E. Nord, and R. Finch Lack of development of new antimicrobial drugs: a potential serious threat to public health Lancet Infect Dis 5 2005 115 1119
18. G. Whittle, N.B. Shoemaker, and A.A. Salyers The role of Bacteroides conjugative transposons in the dissemination of antibiotic resistance genes Cell Mol Life Sci 59 2002 2044 2054
19. H. Smith Questions about the behaviour of bacterial pathogens in vivo Philos Trans R Soc Lond B Biol Sci 355 2000 551 564
20. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 10
21. P.G. Ambrose, S.M. Bhavnani, C.M. Rubino, A. Louie, T. Gumbo, and A. Forrest et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore Clin Infect Dis 44 2007 79 86
22. C. Edlund, L. Barkholt, B. Olsson-Liljequist, and C.E. Nord Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy Clin Infect Dis 25 1997 729 732
23. T.J. Louie, K. Cannon, B. Byrne, J. Emery, L. Ward, and M. Eyben et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI Clin Infect Dis 55 2012 S132 S142
24. D.N. Gerding Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines Discov Med 13 2012 75 83
25. N.K. Surana, and D.L. Kasper The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA Immunol Rev 245 2012 13 26
26. L. Pumbwe, C.A. Skilbeck, and H.M. Wexler The Bacteroides fragilis cell envelope: quarterback, linebacker, coach - or all three? Anaerobe 12 2006 211 220
27. G. Panagiotidis, T. Backstrom, C. Asker-Hagelberg, A. Jandourek, A. Weintraub, and C.E. Nord Effect of ceftaroline on normal human intestinal microflora Antimicrob Agents Chemother 54 2010 1811 18114
28. T. Backstrom, G. Panagiotidis, O. Beck, C. Asker-Hagelberg, M.U. Rashid, and A. Weintraub et al. Effect of ceftobiprole on the normal human intestinal microflora Int J Antimicrob Agents 36 2010 537 541
29. M.U. Rashid, A. Weintraub, and C.E. Nord Effect of telavancin on human intestinal microflora Int J Antimicrob Agents 38 2011 474 479
30. H. Lode, N. Von der Hoh, S. Ziege, K. Borner, and C.E. Nord Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora Scand J Infect Dis 33 2001 899 903